Although vismodegib and sonidegib are the most popular agents that target the transmembrane domain of SMO, there are several other drugs that have a similar mechanism and that have also shown promising results in animal models of medulloblastoma, such as MK-4101, L-4, and nilotinib; however, these agents have not entered clinical trials yet [66]. The gene discussed is SMO; the disease is medulloblastoma.